Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis

Ren Fail. 2007;29(7):927-30. doi: 10.1080/08860220701573640.

Abstract

Fenofibrate, a fibric acid derivative, is used to treat diabetic dyslipidemia, hypertriglyceridemia, and combined hyperlipidemia alone or in combination with statins. Rhabdomyolysis is defined as a pathological condition of skeletal muscle cell damage leading to the release of toxic intracellular material into the circulation. Its major causes include trauma, ischemia, toxins, metabolic disorders, infections, and drugs. Rhabdomyolysis associated with fenofibrate is extremely rare. In nearly all of the presented cases, there was a predisposing factor for rhabdomyolysis such as diabetes, older age, renal insufficiency, and hypothyroidism. Here, we report a nondiabetic, nonhypothyroidic young female patient without any known prior renal disease presenting with acute renal failure developing after fenofibrate treatment.

Publication types

  • Case Reports

MeSH terms

  • Acute Kidney Injury / etiology*
  • Adult
  • Creatine Kinase / blood
  • Female
  • Fenofibrate / adverse effects*
  • Humans
  • Hypolipidemic Agents / adverse effects*
  • Rhabdomyolysis / chemically induced*
  • Rhabdomyolysis / complications*

Substances

  • Hypolipidemic Agents
  • Creatine Kinase
  • Fenofibrate